Pfizer Inc. $PFE Stock Holdings Increased by Tounjian Advisory Partners LLC

Tounjian Advisory Partners LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 42.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 70,982 shares of the biopharmaceutical company’s stock after purchasing an additional 21,126 shares during the quarter. Tounjian Advisory Partners LLC’s holdings in Pfizer were worth $1,809,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Norges Bank purchased a new stake in shares of Pfizer in the second quarter worth approximately $2,270,157,000. Vanguard Group Inc. grew its position in Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Pfizer by 43.4% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock valued at $453,747,000 after buying an additional 5,662,309 shares during the period. Assenagon Asset Management S.A. lifted its position in Pfizer by 75.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock worth $221,398,000 after buying an additional 3,722,531 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Pfizer by 84.9% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock worth $183,302,000 after buying an additional 3,472,240 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched a Phase 2 study of an mRNA influenza vaccine, advancing its mRNA platform into a large seasonal market — a successful program could drive multi-year upside and higher-margin sales. Pfizer Advances mRNA Flu Vaccine Pipeline With New Phase 2 Trial
• Positive Sentiment: Pfizer updated a Phase 1 study for a new obesity injectable — progress in obesity therapeutics targets a very large market and would materially diversify revenue if clinical development continues to advance. Pfizer Quietly Advances New Obesity Shot With Fresh Phase 1 Study Update
• Positive Sentiment: The FDA granted full approval to Pfizer’s BRAFTOVI regimen for first‑line treatment of BRAF V600E-mutant metastatic colorectal cancer (mCRC), converting prior accelerated approval — this expands the label and reduces regulatory risk, supporting near‑term oncology sales. Pfizer Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC
• Positive Sentiment: Income-focused narratives are supporting demand: coverage and write-ups highlighting Pfizer’s attractive dividend (yield cited >6% by some outlets) are drawing investor interest into the stock as a yield play. Love Dividends? 1 Stock to Buy Now With a Yield Over 6%
• Neutral Sentiment: Analysts at Zacks moved Pfizer from “strong sell” to “hold,” which reduces immediate downside narrative but is not a strong buy signal. Zacks upgrade to Hold
• Neutral Sentiment: Recent quarterly results beat EPS and revenue estimates, showing operating resilience despite slight year‑over‑year revenue decline — supports the stock’s valuation but doesn’t eliminate structural concerns.
• Negative Sentiment: RBC Capital initiated coverage with an Underperform and $25 target, warning of a projected $15B–$20B structural revenue decline through 2030 — this report injects a bearish, long‑term revenue risk narrative that can cap upside. RBC Initiates with $25 Target

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Scotiabank started coverage on shares of Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target on the stock. The Goldman Sachs Group restated a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research note on Wednesday, November 5th. Morgan Stanley lowered their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Finally, HSBC reissued a “buy” rating and issued a $29.00 target price on shares of Pfizer in a research report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $27.70.

Pfizer Stock Up 1.9%

Shares of PFE stock opened at $27.61 on Friday. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The stock has a fifty day moving average price of $26.13 and a 200 day moving average price of $25.41. The stock has a market cap of $156.97 billion, a P/E ratio of 20.30 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.63 earnings per share. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.